CRDF - Company ID 0001213037
The table below shows Cardiff Oncology, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $593.00K | $683.00K | $488.00K | $386.00K | $359.00K | $365.99K |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | - | - | - | $27.10M | $17.40M | $11.24M |
| SG&A |
Cardiff Oncology, Inc. reported annual revenue of $593.00K for fiscal year 2025. That is down 13.2% from $683.00K in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $381.07K (FY 2016) to $593.00K. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $14.22M |
| $12.48M |
| $13.04M |
| $13.18M |
| $11.84M |
| $8.22M |
| Operating income | -$48.96M | -$48.65M | -$45.41M | -$39.90M | -$28.86M | -$19.09M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$45.85K | -$45.43K | -$41.44K | -$38.70M | -$28.29M | -$19.31M |
| EPS (diluted) | -$0.69 | -$0.95 | -$0.93 | -$0.89 | -$0.73 | -$1.08 |